Applying intelligently glycemic control and a systematic route through the BBB (blood-brain barrier) to effectively reach neurons. Venture Valuation (VV) interviewed the CEO, Mariko Tosu, PhD
ITO has developed, since its inception in 1916, high-end professional use therapeutic modalities as well as innovative personal use devices. Venture Valuation (VV) interviewed the COO, Mayuko Ito, great-granddaughter of the founder Kenji Ito.
Inspired by co-founder Lea von Bidder’s concept, the Ava bracelet is becoming an indispensable device for women to monitor their own biological rhythms. Venture Valuation (VV) interviewed Vicky Kummer, Global Brand Manager. Read the interview Would you like to be notified about new interviews, reports and other valuable content published by Venture Valuation?
Invented by Prof. Hiroshi Kobayashi, Department of Mechanical Engineering, Tokyo University of Science, the Muscle Suit® is becoming an indispensable device for the elderly care services as well as many other heavy lifting tasks. Venture Valuation (VV) interviewed Takashi Furukawa, CEO. Read the interview Would you like to be notified about new reports and other … Continue reading Interviews with leading Life Sciences companies: Innophys Co.
Current transfusion medicine entirely relies on donated blood. Megakaryon will change the transfusion practices by supplying safe and cost-saving platelets produced in vitro. Mass production in Japan is expected to begin in 2020. Venture Valuation (VV) interviewed Genjiro Miwa, CEO and Founder. Read the interview
Leveraging its proprietary technology of culturing highly purified dendritic cells (DCs), tella is developing, as its first immunotherapeutic product, a DC-based vaccine in combination with WT1 (Wilms’ tumor gene 1) antigen for inoperable pancreatic cancer. Venture Valuation (VV) interviewed Dr. Yuichiro Yazaki, President and CEO. Read the interview
Inventiveness in peptide drug technology and a well thought- out business strategy characterize PeptiDream’s thriving growth. Venture Valuation (VV) interviewed Kiichi Kubota, co-founder and Chairman. Read the interview
By leveraging expertise it has built up over decades in the HERV medical research and development, GeNeuro is engaging in unprecedented therapeutic development targeting HERVs. Venture Valuation (VV) interviewed Jesús Martin-Garcia, co-founder and CEO Read the interview.
ObsEva is specialized in re energizing women’s reproductive and pregnancy therapeutics that have been overlooked and underserved for years. Venture Valuation (VV) interviewed Dr. Ernest Loumaye, co-founder and CEO. Read the interview
Created by two scientists at the École Politechnique Fédérale de Lausanne (EPFL) in 2014 and joined by experienced drug development and business professionals in 2015, Cellestia Biotech AG is developing oral medication along with companion diagnostics for Notch dependent hematological malignancies and solid tumors. Venture Valuation (VV) interviewed the CEO, Dr. Michael Bauer in Basel, … Continue reading Interviews with leading Life Sciences companies: Cellestia Biotech AG